SCHEMBL6482592

SCHEMBL6482592

CSCCCN(CCCSC)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ AHR P35869 2/20 0.37
▸ LMNA P02545 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MAOA P21397 1/20 0.35
▸ PTGER4 P35408 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.33
▸ XDH P47989 1/20 0.33
▸ TNKS O95271 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481323 0.81 MAPT (0.46) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL6483014 0.77 NPC1 (0.42) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL6494373 0.72 MAPT (0.53) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL6372659 0.71 MAPT (0.57) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL22857677 0.69 MAPT (0.50) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL15747045 0.68 MAPT (0.49) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL24900306 0.68 CYP1A2 (0.48) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL10042889 0.67 MAPT (0.52) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL22058423 0.67 MAPT (0.52) MAPTNPC1KDM4EMEN1ALDH1A1
SCHEMBL14295296 0.67 MAPT (0.52) MAPTNPC1KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 — — US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 — — US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 — — US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 — — EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 — — WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 — — US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 — — US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885NPC1 1256/4885KDM4E 1279/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885NPC1 2036/4885KDM4E 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback